Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Trial of Multiple Subcutaneous Injections of GR2301 in Combination With Phototherapy to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy in Trial Participants With Vitiligo

NCT07647237 is registered in ClinicalTrials.gov with Genrix (Shanghai) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07647237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07647237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Trial of Multiple Subcutaneous Injections of GR2301 in Combination With Phototherapy to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy in Trial Participants With Vitiligo
Lead sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
December 31, 2028
Enrollment
116 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

vitiligo